Skip to main content
Fig. 3 | European Journal of Medical Research

Fig. 3

From: Identification of ACBD3 as a new molecular biomarker in pan-cancers through bioinformatic analysis: a preclinical study

Fig. 3

ACBD3 expression in different immune subtypes of various TCGA cancers. Wound healing (C1), IFN-gamma dominant (C2), inflammatory (C3), lymphocyte depleted (C4), immunologically quiet (C5), TGF-b dominant (C6). A bladder urothelial carcinoma (BLCA), B head and neck squamous cell carcinoma (HNSC), C stomach adenocarcinoma (STAD), D skin cutaneous melanoma (SKCM), E sarcoma (SARC), F ovarian serous cystadenocarcinoma (OV), G lung squamous cell carcinoma (LUSC), H liver hepatocellular carcinoma (LIHC), I glioblastoma multiforme (GBM). For the immune subtype of C1, ACBD3 expressed high in BLCA, SKCM, SARC, and LUSC. For the immune subtype of C2, ACBD3 expressed high in HNSC, STAD, and OV. For the immune subtype of C4, ACBD3 expressed high in LIHC, and GBM

Back to article page

European Journal of Medical Research

ISSN: 2047-783X

Contact us